Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
Authors:
- E. FelipEFE. Felip
- S. OrlovSOS. Orlov
- K. ParkKPK. Park
- C.-J. YuCYC.-J. Yu
- C.-M. TsaiCTC.-M. Tsai
- M. NishioMNM. Nishio
- M.C. DolsMDM.C. Dols
- M. McKeageMMM. McKeage
- W.-C. SuWSW.-C. Su
- T.S.K. MokTMT.S.K. Mok
- G. ScagliottiGSG. Scagliotti
- D.R. SpigelDSD.R. Spigel
- 11 October 2016
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi416